DK2970460T3 - Anti-IL-33-antistoffer og anvendelser deraf - Google Patents

Anti-IL-33-antistoffer og anvendelser deraf Download PDF

Info

Publication number: DK2970460T3
Authority: DK; Denmark
Prior art keywords: antibodies
Prior art date: 2013-03-13

Application number

DK14722008.1T

Other languages

English (en)

Inventor

Andrew J Murphy

Nicholas J Papadopoulos

Jamie M Orengo

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-13

Filing date

2014-03-12

Publication date

2020-06-02

2014-03-12 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2020-06-02 Application granted granted Critical

2020-06-02 Publication of DK2970460T3 publication Critical patent/DK2970460T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Microbiology (AREA)
Mycology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Otolaryngology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

DK14722008.1T 2013-03-13 2014-03-12 Anti-IL-33-antistoffer og anvendelser deraf DK2970460T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361778687P	2013-03-13	2013-03-13
US201361819018P	2013-05-03	2013-05-03
PCT/US2014/023930 WO2014164959A2 (en)	2013-03-13	2014-03-12	Anti-il-33 antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
DK2970460T3 true DK2970460T3 (da)	2020-06-02

Family

ID=50678269

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK20159871.1T DK3683235T3 (da)	2013-03-13	2014-03-12	Anti-IL-33-antistoffer og anvendelser deraf
DK14722008.1T DK2970460T3 (da)	2013-03-13	2014-03-12	Anti-IL-33-antistoffer og anvendelser deraf

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK20159871.1T DK3683235T3 (da)	2013-03-13	2014-03-12	Anti-IL-33-antistoffer og anvendelser deraf

Country Status (29)

Country	Link
US (6)	US9453072B2 (da)
EP (3)	EP3683235B1 (da)
JP (2)	JP6479755B2 (da)
KR (1)	KR102103159B1 (da)
CN (1)	CN105051063B (da)
AU (1)	AU2014248839B2 (da)
CA (1)	CA2902172C (da)
CL (2)	CL2015002469A1 (da)
DK (2)	DK3683235T3 (da)
EA (1)	EA031745B1 (da)
ES (2)	ES2983609T3 (da)
FI (1)	FI3683235T3 (da)
HR (2)	HRP20240774T1 (da)
HU (2)	HUE067119T2 (da)
IL (2)	IL240354A0 (da)
JO (1)	JO3532B1 (da)
LT (2)	LT2970460T (da)
MX (2)	MX377712B (da)
MY (3)	MY201923A (da)
PH (1)	PH12015501656A1 (da)
PL (2)	PL2970460T3 (da)
PT (2)	PT3683235T (da)
RS (2)	RS65586B1 (da)
SG (1)	SG11201505745WA (da)
SI (2)	SI2970460T1 (da)
TW (1)	TWI633119B (da)
UY (1)	UY35417A (da)
WO (1)	WO2014164959A2 (da)
ZA (1)	ZA201505376B (da)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG192945A1 (en)	2011-02-25	2013-09-30	Chugai Pharmaceutical Co Ltd	Fcgriib-specific fc antibody
US9890218B2 (en)	2011-06-30	2018-02-13	Chugai Seiyaku Kabushiki Kaisha	Heterodimerized polypeptide
JP6322411B2 (ja)	2011-09-30	2018-05-09	中外製薬株式会社	複数の生理活性を有する抗原の消失を促進する抗原結合分子
JP6124800B2 (ja)	2011-11-30	2017-05-10	中外製薬株式会社	免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
UY34813A (es)	2012-05-18	2013-11-29	Amgen Inc	Proteínas de unión a antígeno dirigidas contra el receptor st2
KR102307248B1 (ko)	2012-08-21	2021-10-01	사노피 바이오테크놀로지	Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
BR112015001955A2 (pt)	2012-08-24	2017-11-07	Chugai Pharmaceutical Co Ltd	variante de região fc específica de fcgamariib
US10766960B2 (en)	2012-12-27	2020-09-08	Chugai Seiyaku Kabushiki Kaisha	Heterodimerized polypeptide
JO3532B1 (ar)	2013-03-13	2020-07-05	Regeneron Pharma	الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
AR095196A1 (es)	2013-03-15	2015-09-30	Regeneron Pharma	Medio de cultivo celular libre de suero
CA2904377C (en)	2013-03-15	2021-07-13	Regeneron Pharmaceuticals, Inc.	Il-33 antagonists and uses thereof
JP6598680B2 (ja)	2013-04-02	2019-10-30	中外製薬株式会社	Ｆｃ領域改変体
TWI563003B (en)	2013-12-26	2016-12-21	Mitsubishi Tanabe Pharma Corp	Human anti-il-33 neutralization monoclonal antibody
MX2016009047A (es) *	2014-01-10	2017-04-13	Anaptysbio Inc	Anticuerpos dirigidos contra interleucina-33 (il-33).
WO2015164354A1 (en)	2014-04-21	2015-10-29	The Childen's Hospital Of Philadelphia	Compositions and methods for treating cytokine-related disorders
NO2785538T3 (da)	2014-05-07	2018-08-04
MX386297B (es)	2014-09-29	2025-03-18	Univ Duke	Moleculas biespecificas que comprenden un brazo orientado a la envoltura vih-1.
US10093730B2 (en) *	2014-11-10	2018-10-09	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
US11708608B2 (en)	2014-11-10	2023-07-25	Genentech, Inc.	Therapeutic and diagnostic methods for IL-33-mediated disorders
EP4600372A3 (en)	2014-12-19	2025-11-19	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CN114773469B (zh)	2015-02-05	2025-12-19	中外制药株式会社	包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
EP3265107B1 (en) *	2015-03-02	2024-10-02	180 Therapeutics LP	Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
AU2016239331C1 (en) *	2015-03-31	2020-01-30	Medimmune Limited	A novel IL33 form, mutated forms of IL33, antibodies, assays and methods of using the same
EP3991848A3 (en) *	2015-04-06	2022-07-20	Meso Scale Technologies, LLC.	High throughput system for performing assays using electrochemiluminescence including a consumable shaking apparatus
TWI899515B (zh)	2015-08-04	2025-10-01	美商再生元醫藥公司	補充牛磺酸之細胞培養基及用法
WO2017062456A2 (en)	2015-10-06	2017-04-13	Regeneron Pharmaceuticals, Inc.	Biomarkers related to interleukin-33 (il-33)-mediated diseases and uses thereof
WO2017110981A1 (en)	2015-12-25	2017-06-29	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies and methods of use
AU2017208099A1 (en) *	2016-01-14	2018-08-09	Anaptysbio, Inc.	Inhibition of allergic reaction using an IL-33 inhibitor
EP3445783A2 (en)	2016-04-18	2019-02-27	Celldex Therapeutics, Inc.	Agonistic antibodies that bind human cd40 and uses thereof
MA45294A (fr) *	2016-04-22	2019-02-27	Medimmune Llc	Plasticité fonctionnelle d'ilc2, immunité et copd
EA037960B1 (ru)	2016-04-27	2021-06-15	Эббви Инк.	Способ лечения эозинофильного эзофагита с применением антитела против il-13
CN109415436A (zh) *	2016-04-27	2019-03-01	辉瑞公司	抗il-33抗体及其组合物、方法及用途
KR102102734B1 (ko)	2016-08-05	2020-04-22	추가이 세이야쿠 가부시키가이샤	Il-8 관련 질환의 치료용 또는 예방용 조성물
EP3504328A1 (en)	2016-08-24	2019-07-03	Regeneron Pharmaceuticals, Inc.	Host cell protein modification
WO2018069500A2 (en) *	2016-10-13	2018-04-19	Symphogen A/S	Anti-lag-3 antibodies and compositions
JOP20190093A1 (ar)	2016-10-28	2019-04-25	Lilly Co Eli	أجسام مضادة لـ il-33 واستخداماتها
TWI784988B (zh) *	2016-12-01	2022-12-01	美商再生元醫藥公司	治療發炎症狀的方法
EP3580240A1 (en)	2017-02-10	2019-12-18	H. Hoffnabb-La Roche Ag	Anti-tryptase antibodies, compositions thereof, and uses thereof
CN108456251A (zh) *	2017-02-21	2018-08-28	上海君实生物医药科技股份有限公司	抗pd-l1抗体及其应用
WO2018156180A1 (en)	2017-02-24	2018-08-30	Kindred Biosciences, Inc.	Anti-il31 antibodies for veterinary use
IL314591A (en)	2017-04-13	2024-09-01	Regeneron Pharma	Treatment and prevention of inflammatory lung diseases in patients with risk alleles in the genes encoding IL33 and IL1RL1
CN118994394A (zh)	2017-06-12	2024-11-22	蓝鳍生物医药公司	抗-il1rap抗体和抗体药物缀合物
CN110914293B (zh)	2017-07-06	2024-08-13	里珍纳龙药品有限公司	用于制备糖蛋白的细胞培养工艺
CN115920031A (zh) *	2017-08-31	2023-04-07	田边三菱制药株式会社	含有il-33拮抗剂的子宫内膜异位症治疗剂
JP7731196B2 (ja)	2017-11-14	2025-08-29	中外製薬株式会社	抗Ｃ１ｓ抗体および使用方法
CA3084059A1 (en)	2017-12-22	2019-06-27	Regeneron Pharmaceuticals, Inc.	System and method for characterizing drug product impurities
BR112020013336A2 (pt)	2018-01-31	2020-12-01	Regeneron Pharmaceuticals, Inc.	produto farmacêutico proteico, métodos para caracterizar as impurezas do produto farmacêutico proteico de alto peso molecular intermediário, para produção de um anticorpo, e para caracterizar as impurezas de fármaco com variação de carga, anticorpo, e, sistema para caracterizar impurezas de fármaco de alto peso molecular intermediário.
TWI786265B (zh)	2018-02-02	2022-12-11	美商再生元醫藥公司	用於表徵蛋白質二聚合之系統及方法
BR112020016172A2 (pt)	2018-02-09	2020-12-15	Genentech, Inc.	Métodos de tratamento, métodos para determinar, métodos para selecionar uma terapia, métodos para avaliar uma resposta e monitorar a resposta, kits para identificar um paciente, agentes selecionados, agentes para uso, uso de um agente selecionado e uso de um antagonista
KR20260004591A (ko)	2018-02-28	2026-01-08	리제너론 파마슈티칼스 인코포레이티드	바이러스 오염물질을 확인하기 위한 시스템 및 방법
US12253490B2 (en)	2018-03-19	2025-03-18	Regeneron Pharmaceuticals, Inc.	Microchip capillary electrophoresis assays and reagents
US12259355B2 (en)	2018-03-19	2025-03-25	Regeneron Pharmaceuticals, Inc.	Microchip capillary electrophoresis assays and reagents
IL277264B2 (en)	2018-03-19	2024-03-01	Regeneron Pharma	Microchip capillary electrophoresis assays and reagents
IL277890B2 (en)	2018-04-11	2024-03-01	Regeneron Pharma	Methods for quantifying il-33
TW202016125A (zh)	2018-05-10	2020-05-01	美商再生元醫藥公司	用於定量及調節蛋白質黏度之系統與方法
CN112839960B (zh)	2018-08-10	2024-09-06	中外制药株式会社	抗cd137抗原结合分子及其应用
AU2019329686A1 (en)	2018-08-27	2020-12-03	Regeneron Pharmaceuticals, Inc.	Use of raman spectroscopy in downstream purification
AU2019333047A1 (en)	2018-08-30	2020-12-03	Regeneron Pharmaceuticals, Inc.	Methods for characterizing protein complexes
US11579150B2 (en)	2019-01-16	2023-02-14	Regeneron Pharmaceuticals, Inc.	Methods for characterizing disulfide bonds
TW202519263A (zh)	2019-03-21	2025-05-16	美商再生元醫藥公司	含有抗il-33抗體之穩定調配物
KR20220004708A (ko) *	2019-05-01	2022-01-11	사노피 바이오테크놀로지	Il-33 길항제를 투여하여 천식을 치료 또는 예방하는 방법
KR20220007586A (ko)	2019-05-13	2022-01-18	리제너론 파마슈티칼스 인코포레이티드	개선된 경쟁적 리간드 결합 검정
CN119798452A (zh)	2019-05-15	2025-04-11	中外制药株式会社	抗原结合分子、药物组合物和方法
BR112022000740A2 (pt)	2019-07-16	2022-07-05	Sanofi Biotechnology	Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
CN114667450B (zh)	2019-09-24	2025-05-02	里珍纳龙药品有限公司	用于色谱介质的使用和再生的系统及方法
WO2021064452A1 (en)	2019-10-03	2021-04-08	Dasman Diabetes Institute	Method for preventing progression to type ii diabetes
US12297451B1 (en)	2019-10-25	2025-05-13	Regeneron Pharmaceuticals, Inc.	Cell culture medium
JP2023501316A (ja)	2019-11-04	2023-01-18	メドイミューン・リミテッド	腎機能障害を治療するための抗ｉｌ－３３治療薬
EP4054711A1 (en)	2019-11-04	2022-09-14	MedImmune Limited	Methods of using il-33 antagonists
BR112022009974A2 (pt)	2019-11-25	2022-08-16	Regeneron Pharma	Métodos de produção de um polímero ou micropartículas revestidas com polímero, para produzir microesferas poliméricas ou revestidas com polímero e para produzir micropartículas, composição de liberação sustentada, micropartículas, e, composição farmacêutica
JP2023508360A (ja) *	2019-12-23	2023-03-02	サノフィ・バイオテクノロジー	Ｉｌ－３３アンタゴニストおよび／またはｉｌ－４ｒアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法
CA3165060C (en)	2020-01-21	2023-06-20	Yiming Zhao	Deglycosylation methods for electrophoresis of glycosylated proteins
CN113214395A (zh) *	2020-01-21	2021-08-06	迈威(上海)生物科技股份有限公司	抗st2抗体及其应用
JP7767298B2 (ja)	2020-03-13	2025-11-11	ジェネンテック，インコーポレイテッド	抗インターロイキン－３３抗体及びその使用
JP2023516497A (ja)	2020-03-13	2023-04-19	メドイミューン・リミテッド	Ｉｌ３３にリスクアレルを有する対象を治療するための治療方法
WO2021204707A1 (en)	2020-04-06	2021-10-14	Medimmune Limited	Treating acute respiratory distress syndrome with il-33 axis binding antagonists
WO2021211414A1 (en) *	2020-04-13	2021-10-21	Maddon Advisors Llc	Bispecific antibody compositions and methods for treating covid-19
AU2021270839B2 (en)	2020-05-11	2025-01-02	Medimmune Limited	Formulations of anti-IL-33 antibodies
EP4151654A4 (en) *	2020-05-12	2024-11-27	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	St2 antigen binding protein
KR102789102B1 (ko) *	2020-08-18	2025-03-28	성균관대학교산학협력단	Il-33 항체 또는 이의 항원 결합 단편
TW202432837A (zh)	2020-08-31	2024-08-16	美商再生元醫藥公司	用以改良細胞培養效能及減少天冬醯胺序列變異之天冬醯胺饋料策略
CN114249825A (zh) *	2020-09-25	2022-03-29	三生国健药业（上海）股份有限公司	结合人il-33的抗体、其制备方法和用途
WO2022115588A1 (en)	2020-11-25	2022-06-02	Regeneron Pharmaceuticals, Inc.	Sustained release formulations using non-aqueous membrane emulsification
CN116710124A (zh)	2020-12-17	2023-09-05	瑞泽恩制药公司	包封蛋白质的微凝胶的制造
AU2022209730A1 (en)	2021-01-20	2023-07-13	Regeneron Pharmaceuticals, Inc.	Methods of improving protein titer in cell culture
BR112023017442A2 (pt)	2021-03-03	2023-09-26	Regeneron Pharma	Métodos para identificar regiões em uma proteína e para modificar a viscosidade de uma droga proteica, e, droga proteica
BR112023018665A2 (pt)	2021-03-26	2023-10-03	Regeneron Pharma	Métodos e sistemas para desenvolvimento de protocolos de mistura
KR20240015646A (ko)	2021-06-01	2024-02-05	리제너론 파마슈티칼스 인코포레이티드	마이크로칩 모세관 전기영동 분석 및 시약
CN113493513B (zh) *	2021-06-30	2022-07-12	深圳大学	抗人il-33中和性自身抗体及其制备方法和应用
CN113603775B (zh)	2021-09-03	2022-05-20	江苏荃信生物医药股份有限公司	抗人白介素-33单克隆抗体及其应用
US20230077710A1 (en)	2021-09-08	2023-03-16	Regeneron Pharmaceuticals, Inc.	HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
CA3232463A1 (en)	2021-09-20	2023-03-23	Philip Mellors	Methods of controlling antibody heterogeneity
US20230110811A1 (en)	2021-10-07	2023-04-13	Regeneron Pharmaceuticals, Inc.	pH METER CALIBRATION AND CORRECTION
IL311245A (en)	2021-10-07	2024-05-01	Regeneron Pharma	Systems and methods for pH modeling and control
EP4423018A1 (en)	2021-10-26	2024-09-04	Regeneron Pharmaceuticals, Inc.	Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
EP4430072A1 (en)	2021-11-10	2024-09-18	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
PE20242075A1 (es) *	2022-03-03	2024-10-18	Pfizer	Anticuerpos multiespecificos y usos de estos
AU2023233590A1 (en)	2022-03-18	2024-10-17	Regeneron Pharmaceuticals, Inc.	Methods and systems for analyzing polypeptide variants
TW202402790A (zh)	2022-03-25	2024-01-16	英商梅迪繆思有限公司	減少呼吸系統感染之方法
JP2025530672A (ja)	2022-08-19	2025-09-17	メディミューンリミテッド	Ｉｌ－３３軸アンタゴニストによる処置のために患者を選択する方法
WO2024130048A1 (en)	2022-12-16	2024-06-20	Regeneron Pharmaceuticals, Inc.	Methods and systems for assessing chromatographic column integrity
US20240245779A1 (en)	2023-01-25	2024-07-25	Regeneron Pharmaceuticals, Inc.	Methods of modeling liquid protein composition stability
EP4655595A1 (en)	2023-01-25	2025-12-03	Regeneron Pharmaceuticals, Inc.	Mass spectrometry-based characterization of antibodies co-expressed in vivo
US20240255519A1 (en)	2023-02-01	2024-08-01	Regeneron Pharmaceuticals, Inc.	Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
WO2024178213A2 (en)	2023-02-22	2024-08-29	Regeneron Pharmaceuticals, Inc.	System suitability parameters and column aging
US20240366471A1 (en)	2023-05-01	2024-11-07	Regeneron Pharmaceuticals, Inc.	Multidose antibody drug products using phenol or benzyl alcohol
KR102773101B1 (ko)	2023-08-28	2025-02-26	서울대학교산학협력단	세포독성능을 갖는 제2형 선천성 림프구 세포, 이의 제조방법 및 용도
JP7668943B2 (ja) *	2023-08-30	2025-04-25	ファイザー・インク	多重特異性抗体およびその使用
WO2025054406A1 (en)	2023-09-08	2025-03-13	Regeneron Pharmaceuticals, Inc.	Methods and systems for assessing chromatographic column integrity
US20250095773A1 (en)	2023-09-18	2025-03-20	Regeneron Pharmaceuticals, Inc.	Methods and systems for developing chromatography protocols
WO2025072597A2 (en)	2023-09-29	2025-04-03	Regeneron Pharmaceuticals, Inc.	Lyophilization using controlled nucleation
US20250129117A1 (en)	2023-10-18	2025-04-24	Regeneron Pharmaceuticals, Inc.	Rapid purification of monoclonal antibody from in-process upstream cell culture material
TW202535934A (zh)	2023-11-02	2025-09-16	美商再生元醫藥公司	利用應力來降低脂酶活性的方法
WO2025120567A1 (en)	2023-12-07	2025-06-12	Medimmune Limited	Method of treatment of asthma
TW202535949A (zh)	2023-12-20	2025-09-16	美商必治妥美雅史谷比公司	靶向IL-18受體β(IL-18RB)之抗體及相關方法
WO2025166281A1 (en)	2024-02-01	2025-08-07	Regeneron Pharmaceuticals, Inc.	Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en)	2024-02-16	2025-08-21	Regeneron Pharmaceuticals, Inc.	Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en)	2024-03-15	2025-09-18	Regeneron Pharmaceuticals, Inc.	Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
TW202540173A (zh)	2024-04-04	2025-10-16	英商梅迪繆思有限公司	治療及選擇對象之方法
WO2025242618A1 (en)	2024-05-20	2025-11-27	Medimmune Limited	Bronchiectasis treatment
WO2025259840A1 (en)	2024-06-13	2025-12-18	Regeneron Pharmaceuticals, Inc.	Methods and systems for scaled chromatography
WO2026025028A1 (en)	2024-07-26	2026-01-29	Regeneron Pharmaceuticals, Inc.	Methods of making ultra-high concentrated protein formulations using lyophilization

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US550362A (en)		1895-11-26		crosby
US1000056A (en)	1910-11-03	1911-08-08	Carlos Van Bergh	Threshing-machine.
US1001164A (en)	1911-06-09	1911-08-22	Arthur W Porter	Cotton-sweep.
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE69233254T2 (de)	1991-06-14	2004-09-16	Genentech, Inc., South San Francisco	Humanisierter Heregulin Antikörper
US5576191A (en)	1994-06-17	1996-11-19	Immunex Corporation	Cytokine that binds ST2
US20070042978A1 (en)	2002-12-19	2007-02-22	Jean-Philippe Girard	Nf-hev compositions and methods of use
NZ549040A (en) *	2004-02-17	2009-07-31	Schering Corp	Use for interleukin-33 (IL33) and the IL-33 receptor complex
EP1740946B1 (en)	2004-04-20	2013-11-06	Genmab A/S	Human monoclonal antibodies against cd20
US7666622B2 (en)	2005-10-19	2010-02-23	Regeneron Pharmaceuticals, Inc.	Monomeric self-associating fusion polypeptides and therapeutic uses thereof
WO2007140205A2 (en)	2006-05-24	2007-12-06	Biogen Idec Ma Inc.	Methods of treating fibrosis
SI2041177T1 (sl)	2006-06-02	2012-03-30	Regeneron Pharma	Visoko afinitetna protitelesa za humani IL receptor
US7560530B1 (en)	2006-07-20	2009-07-14	Schering Corporation	IL-33 receptor
IE20080331A1 (en)	2007-04-26	2009-07-08	Trinity College Dublin	Products for altering cytokine activity and methods therefor
EP2069784A4 (en)	2007-05-18	2009-11-18	Medimmune Llc	IL-33 IN INFLAMMATORY DISEASE
EP2211905A1 (en)	2007-10-26	2010-08-04	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Inhibitors of caspase i-dependent cytokines in the treatment of neurodegenerative disorders
WO2011031600A1 (en)	2009-09-10	2011-03-17	Schering Corporation	Use of il-33 antagonists to treat fibrotic disease
US9212227B2 (en)	2012-04-30	2015-12-15	Janssen Biotech, Inc.	ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
UY34813A (es)	2012-05-18	2013-11-29	Amgen Inc	Proteínas de unión a antígeno dirigidas contra el receptor st2
JO3532B1 (ar)	2013-03-13	2020-07-05	Regeneron Pharma	الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
CA2904377C (en)	2013-03-15	2021-07-13	Regeneron Pharmaceuticals, Inc.	Il-33 antagonists and uses thereof
TWI563003B (en)	2013-12-26	2016-12-21	Mitsubishi Tanabe Pharma Corp	Human anti-il-33 neutralization monoclonal antibody
MX2016009047A (es)	2014-01-10	2017-04-13	Anaptysbio Inc	Anticuerpos dirigidos contra interleucina-33 (il-33).

2014
- 2014-03-09 JO JOP/2014/0080A patent/JO3532B1/ar active
- 2014-03-11 TW TW103108304A patent/TWI633119B/zh active
- 2014-03-12 HU HUE20159871A patent/HUE067119T2/hu unknown
- 2014-03-12 EP EP20159871.1A patent/EP3683235B1/en active Active
- 2014-03-12 WO PCT/US2014/023930 patent/WO2014164959A2/en not_active Ceased
- 2014-03-12 PT PT201598711T patent/PT3683235T/pt unknown
- 2014-03-12 DK DK20159871.1T patent/DK3683235T3/da active
- 2014-03-12 SI SI201431574T patent/SI2970460T1/sl unknown
- 2014-03-12 HR HRP20240774TT patent/HRP20240774T1/hr unknown
- 2014-03-12 MY MYPI2019007720A patent/MY201923A/en unknown
- 2014-03-12 LT LTEP14722008.1T patent/LT2970460T/lt unknown
- 2014-03-12 CN CN201480014548.XA patent/CN105051063B/zh active Active
- 2014-03-12 HR HRP20200846TT patent/HRP20200846T1/hr unknown
- 2014-03-12 CA CA2902172A patent/CA2902172C/en active Active
- 2014-03-12 HU HUE14722008A patent/HUE051018T2/hu unknown
- 2014-03-12 LT LTEP20159871.1T patent/LT3683235T/lt unknown
- 2014-03-12 KR KR1020157021200A patent/KR102103159B1/ko active Active
- 2014-03-12 RS RS20240631A patent/RS65586B1/sr unknown
- 2014-03-12 EP EP24170532.6A patent/EP4403570A3/en active Pending
- 2014-03-12 ES ES20159871T patent/ES2983609T3/es active Active
- 2014-03-12 PT PT147220081T patent/PT2970460T/pt unknown
- 2014-03-12 DK DK14722008.1T patent/DK2970460T3/da active
- 2014-03-12 PL PL14722008T patent/PL2970460T3/pl unknown
- 2014-03-12 JP JP2016501386A patent/JP6479755B2/ja active Active
- 2014-03-12 EA EA201591716A patent/EA031745B1/ru unknown
- 2014-03-12 MY MYPI2022005368A patent/MY209528A/en unknown
- 2014-03-12 SI SI201432077T patent/SI3683235T1/sl unknown
- 2014-03-12 RS RS20200801A patent/RS60503B1/sr unknown
- 2014-03-12 ES ES14722008T patent/ES2804592T3/es active Active
- 2014-03-12 EP EP14722008.1A patent/EP2970460B1/en active Active
- 2014-03-12 US US14/205,512 patent/US9453072B2/en active Active
- 2014-03-12 SG SG11201505745WA patent/SG11201505745WA/en unknown
- 2014-03-12 MX MX2015010599A patent/MX377712B/es active IP Right Grant
- 2014-03-12 FI FIEP20159871.1T patent/FI3683235T3/fi active
- 2014-03-12 AU AU2014248839A patent/AU2014248839B2/en active Active
- 2014-03-12 MY MYPI2015702406A patent/MY174740A/en unknown
- 2014-03-12 PL PL20159871.1T patent/PL3683235T3/pl unknown
- 2014-03-13 UY UY0001035417A patent/UY35417A/es not_active Application Discontinuation
2015
- 2015-07-24 ZA ZA2015/05376A patent/ZA201505376B/en unknown
- 2015-07-24 PH PH12015501656A patent/PH12015501656A1/en unknown
- 2015-08-04 IL IL240354A patent/IL240354A0/en unknown
- 2015-08-17 MX MX2020012416A patent/MX2020012416A/es unknown
- 2015-09-04 CL CL2015002469A patent/CL2015002469A1/es unknown
2016
- 2016-08-26 US US15/248,348 patent/US10000564B2/en active Active
2018
- 2018-01-12 CL CL2018000101A patent/CL2018000101A1/es unknown
- 2018-05-14 US US15/979,187 patent/US10519230B2/en active Active
- 2018-09-13 IL IL261743A patent/IL261743B/en active IP Right Grant
2019
- 2019-02-05 JP JP2019018423A patent/JP6845876B2/ja active Active
- 2019-11-18 US US16/687,257 patent/US11104729B2/en active Active
2021
- 2021-07-29 US US17/388,322 patent/US12037388B2/en active Active
2024
- 2024-06-05 US US18/734,956 patent/US20240425580A1/en active Pending

Also Published As

Publication number	Publication date
US20210363236A1 (en)	2021-11-25
SI3683235T1 (sl)	2024-07-31
ZA201505376B (en)	2016-07-27
US20160362487A1 (en)	2016-12-15
PT3683235T (pt)	2024-06-24
US20240425580A1 (en)	2024-12-26
HUE051018T2 (hu)	2021-01-28
JO3532B1 (ar)	2020-07-05
IL240354A0 (en)	2015-09-24
HRP20240774T1 (hr)	2024-09-13
RS60503B1 (sr)	2020-08-31
US20140271658A1 (en)	2014-09-18
EP2970460B1 (en)	2020-04-29
EP4403570A2 (en)	2024-07-24
IL261743B (en)	2020-11-30
HRP20200846T1 (hr)	2020-08-21
LT3683235T (lt)	2024-06-25
TWI633119B (zh)	2018-08-21
AU2014248839A1 (en)	2015-08-20
WO2014164959A2 (en)	2014-10-09
WO2014164959A3 (en)	2015-02-19
US10000564B2 (en)	2018-06-19
SI2970460T1 (sl)	2020-07-31
PH12015501656B1 (en)	2015-10-19
HUE067119T2 (hu)	2024-10-28
JP6479755B2 (ja)	2019-03-06
MX2020012416A (es)	2021-02-09
US20180251542A1 (en)	2018-09-06
TW201522370A (zh)	2015-06-16
HK1220467A1 (en)	2017-05-05
EA031745B1 (ru)	2019-02-28
MY174740A (en)	2020-05-13
US11104729B2 (en)	2021-08-31
CN105051063B (zh)	2019-08-16
PL2970460T3 (pl)	2020-10-05
AU2014248839B2 (en)	2019-01-03
DK3683235T3 (da)	2024-07-08
CN105051063A (zh)	2015-11-11
ES2983609T3 (es)	2024-10-23
KR102103159B1 (ko)	2020-05-29
PT2970460T (pt)	2020-06-02
CA2902172C (en)	2024-04-02
EA201591716A1 (ru)	2016-07-29
KR20150126598A (ko)	2015-11-12
EP4403570A3 (en)	2024-10-02
EP3683235A1 (en)	2020-07-22
ES2804592T3 (es)	2021-02-08
MY201923A (en)	2024-03-23
PH12015501656A1 (en)	2015-10-19
US10519230B2 (en)	2019-12-31
EP3683235B1 (en)	2024-05-22
MX377712B (es)	2025-03-11
US9453072B2 (en)	2016-09-27
PL3683235T3 (pl)	2024-08-05
CA2902172A1 (en)	2014-10-09
US20200071396A1 (en)	2020-03-05
RS65586B1 (sr)	2024-06-28
IL261743A (en)	2018-10-31
CL2015002469A1 (es)	2016-06-10
MY209528A (en)	2025-07-17
UY35417A (es)	2014-10-31
MX2015010599A (es)	2015-12-15
JP6845876B2 (ja)	2021-03-24
LT2970460T (lt)	2020-06-10
BR112015020470A2 (pt)	2017-10-10
JP2016513644A (ja)	2016-05-16
FI3683235T3 (fi)	2024-07-02
SG11201505745WA (en)	2015-08-28
JP2019088311A (ja)	2019-06-13
CL2018000101A1 (es)	2018-07-06
US12037388B2 (en)	2024-07-16
NZ710831A (en)	2021-04-30
EP2970460A2 (en)	2016-01-20

Publication	Publication Date	Title
IL290972A (en)	2022-05-01	Anti-vista antibodies and fragments
DK2970460T3 (da)	2020-06-02	Anti-IL-33-antistoffer og anvendelser deraf
DK3089994T3 (da)	2022-07-04	Fabs-in-tandem-immunglobulin og anvendelser deraf
DK3027209T3 (da)	2020-11-02	Anti-Activin A-antistoffer og anvendelser deraf
DK3043784T3 (da)	2019-07-15	Arylethere og anvendelser deraf
DK2914291T3 (da)	2022-05-16	Anti-komplement-c1s-antistoffer og anvendelser deraf
DK3003039T3 (da)	2021-05-25	Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK3026062T3 (da)	2020-10-12	Anti-pd-1-antistof og anvendelse deraf
DK3736291T5 (da)	2024-08-26	Anti-FCRH5-antistoffer
DK3333191T3 (da)	2020-10-26	Anti-C10ORF54-antistoffer og anvendelser deraf
DK3126388T3 (da)	2019-07-29	Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3079719T3 (da)	2019-11-18	ANTI-SIGLEC-8-antistoffer og fremgangsmåder til anvendelse deraf
CL2015001924A1 (es)	2016-06-10	Anticuerpos anti-pdgfr-beta y usos relacionados.
DK3708583T3 (da)	2022-05-16	Ikke-fucosylerede anti-fgfr2iiib-antistoffer
DK3027204T3 (da)	2022-04-19	Flerdelte signaleringsproteiner og anvendelser deraf
DK2968443T3 (da)	2021-12-06	Hepcidinanaloger og anvendelser deraf
IL245036B (en)	2020-10-29	Pesticidal compositions and related methods
LT3192812T (lt)	2020-08-10	Anti-cd3 antikūnai ir jų panaudojimo būdai
DK2962100T3 (da)	2021-11-01	Tuberkulosebiomarkører og anvendelser deraf
DK3381943T3 (da)	2022-05-16	Anti-kit-antistoffer og anvendelser deraf
DK3063144T3 (da)	2021-10-25	Antiparasitære og pesticid-isoxazolinforbindelser
DK3086807T3 (da)	2022-09-19	Antistoffer og fremgangsmåder til anvendelse
DK3030549T3 (da)	2019-05-13	Pyridazinonforbindelser og anvendelser deraf
DK3077467T3 (da)	2023-01-09	Sikkativsammensætning og anvendelse deraf
DK3004162T3 (da)	2020-05-18	Anti-væg-teichoin-antistoffer og konjugater